Skip to main content
SpringerLink
Log in

Practice-changing strategies in the treatment of esophageal cancer

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

For patients suffering from localized and advanced stage esophageal cancer, long-term outcomes remain poor. However, as already seen in other tumors, the introduction of immune checkpoint inhibitors has led to practice-changing results in the treatment of esophageal cancer. In this short review, five emerging studies are presented and discussed, which have changed standard of care in this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Cited Literature

  1. Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Google Scholar 

  2. International Agency for Research on Cancer, WHO. Globocan. China. 2020.

    Google Scholar 

  3. Arnold M, et al. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut. 2020;69(9):1564–71.

    Article  Google Scholar 

  4. Hou H, et al. Survival of esophageal cancer in China: a pooled analysis on hospital-based studies from 2000 to 2018. Front Oncol. 2019;9:548.

    Article  Google Scholar 

  5. van Hagen P, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.

    Article  Google Scholar 

  6. Sjoquist KM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy forresectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92.

    Article  Google Scholar 

  7. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–1195.

    Article  Google Scholar 

  8. Kelly RJ, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): first results of the checkmate 577 study. Ann Oncol. 2020;31(4):S1142–S215.

    Google Scholar 

  9. Kato K, Sun J, Shah MA. Pembrolizumab plus chemotherapy versus chemotherapy as first line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study. Ann Oncol. 2020;31(4):S1142–S215.

    Google Scholar 

  10. Chau I, Doki Y, Ajani JA, et al. Nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: first results of the checkmate 648 study. 2021 ASCO Annual Meeting. 2021. Abstract 4001.

    Google Scholar 

  11. Kojima T, Shah MA, Muro K, et al. KEYNOTE-181 investigators. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–48.

    Article  CAS  Google Scholar 

  12. Kato K, Cho B, Takahashi M, Okada M, Lin C, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase III trial. Lancet Oncol. 2019;20:1506–17.

    Article  CAS  Google Scholar 

Further Reading

  1. Xu RH, Luo H, Lu J, et al. ESCORT-1st: a randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy vs chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC). J Clin Oncol. 2021; https://doi.org/10.1200/JCO.2021.39.15_suppl.4000.

    Article  PubMed  Google Scholar 

  2. Shen L, Lu Z‑H, Wang J‑Y, et al. Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastaticesophageal squamous cell cancer: first results of the phase III ORIENT-15 study. European Society for Medical Oncology Congress; September 16–21, 2021. 2021. Abstract LBA52.

    Google Scholar 

  3. Xu J, Jiang H, Pan Y, et al. Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric orgastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT- 16: first results of a randomized, double-blind,phase III study. European Society for Medical Oncology Congress; September 16–21, 2021. 2021. Abstract LBA53.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Hematology and Palliative Care, Klinik Ottakring, Vienna, Austria, Montlearstraße 37, 1160

    Ercan Müldür MD & Wolfgang Hilbe MD

Authors
  1. Ercan Müldür MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Hilbe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ercan Müldür MD.

Ethics declarations

Conflict of interest

E. Müldür and W. Hilbe declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Müldür, E., Hilbe, W. Practice-changing strategies in the treatment of esophageal cancer. memo 15, 35–38 (2022). https://doi.org/10.1007/s12254-021-00779-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-021-00779-1

Keywords

Search

Navigation